Clinical Outcomes of Rivaroxaban versus LMWH Thromboprophylaxis Following Gynecologic Cancer Surgery: A Retrospective Comparison Study
- 1Department of Pharmacy, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China
Abstract
Purpose: We aimed to evaluate the clinical outcomes of rivaroxaban vs low-molecular-weight heparin (LMWH) for thromboprophylaxis following gynecologic cancer surgery.
Patients and Methods: We conducted a retrospective comparative study of rivaroxaban vs standard LMWH in patients undergoing gynecologic malignancy surgery. Clinical outcomes included venous thromboembolism (VTE), major bleeding, non-major bleeding, and 1-year all-cause mortality. A multivariable logistic regression model was used to adjust for potential confounding factors.
Results: A total of 250 women were included, 134 received rivaroxaban and 116 received LMWH for postoperative thromboprophylaxis following gynecologic malignancy-related surgery. After adjusting for potential confounding factors using multivariable logistic regression, the 30-day VTE and bleeding events showed no significant differences between the rivaroxaban group and the LMWH groups. There were no cases of 30-day readmission related to surgery, no 30-day mortality, and no all-cause mortality during the 1-year follow-up. Notably, all distal DVT events in both groups were calf muscular vein thromboses. During the 1-year follow-up, no patients were rehospitalized or died due to VTE.
Conclusion: We observed no significant differences in short- and long-term outcomes between rivaroxaban and LMWH after gynecologic malignancy surgery. Given the retrospective design and limited number of events, these results should be interpreted with caution, and prospective randomized studies are warranted.
Related
- Urinary complications following Bricker urinary diversion in gynecologic cancer: A retrospective analysis of 77 cases
- Comparison of surgical outcomes, safety, and cosmetic satisfaction between immediate implant-based and transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction following total mastectomy: a retrospective cohort study
- Association between delayed thromboprophylaxis and the incidence of deep vein thrombosis in patients with pelvic trauma: a retrospective cohort adjusted for severity at a level I trauma center
- Pharmacological thromboprophylaxis following ventriculoperitoneal shunt insertion: a single-centre experience of thromboembolic and bleeding outcomes
- Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study
BibTeX
@article{zhou2026clinical,
title = {{Clinical Outcomes of Rivaroxaban versus LMWH Thromboprophylaxis Following Gynecologic Cancer Surgery: A Retrospective Comparison Study}},
author = {Hong Zhou and Ting Wei and Huanrui Zheng and Jinhua Zhang},
journal = {International Journal of Women's Health},
year = {2026},
month = nov,
doi = {10.2147/ijwh.s648285},
url = {https://doi.org/10.2147/ijwh.s648285},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Clinical Outcomes of Rivaroxaban versus LMWH Thromboprophylaxis Following Gynecologic Cancer Surgery: A Retrospective Comparison Study
AU - Hong Zhou
AU - Ting Wei
AU - Huanrui Zheng
AU - Jinhua Zhang
PY - 2026
DA - 2026/11/05
JO - International Journal of Women's Health
DO - 10.2147/ijwh.s648285
UR - https://doi.org/10.2147/ijwh.s648285
AB - Purpose: We aimed to evaluate the clinical outcomes of rivaroxaban vs low-molecular-weight heparin (LMWH) for thromboprophylaxis following gynecologic cancer surgery. Patients and Methods: We conducted a retrospective comparative study of rivaroxaban vs standard LMWH in patients undergoing gynecologic malignancy surgery. Clinical outcomes included venous thromboembolism (VTE), major bleeding, non-major bleeding, and 1-year all-cause mortality. A multivariable logistic regression model was used to adjust for potential confounding factors. Results: A total of 250 women were included, 134 received rivaroxaban and 116 received LMWH for postoperative thromboprophylaxis following gynecologic malignancy-related surgery. After adjusting for potential confounding factors using multivariable logistic regression, the 30-day VTE and bleeding events showed no significant differences between the rivaroxaban group and the LMWH groups. There were no cases of 30-day readmission related to surgery, no 30-day mortality, and no all-cause mortality during the 1-year follow-up. Notably, all distal DVT events in both groups were calf muscular vein thromboses. During the 1-year follow-up, no patients were rehospitalized or died due to VTE. Conclusion: We observed no significant differences in short- and long-term outcomes between rivaroxaban and LMWH after gynecologic malignancy surgery. Given the retrospective design and limited number of events, these results should be interpreted with caution, and prospective randomized studies are warranted.
SN - 1179-1411
ER -